Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough News – Experts Weigh In
What to Know Before Markets Open on October 20, 2025 FDA Breakthrough News Ignites Rally Spruce Biosciences’ meteoric rise began with a game-changing regulatory win. On October 6, the company announced that the FDA had granted Breakthrough Therapy Designation (BTD) to its lead drug, tralesinidase alfa (TA-ERT) ts2.tech. TA-ERT is an experimental enzyme replacement therapy targeting Sanfilippo Syndrome Type B (also known as MPS IIIB) – a rare, inherited lysosomal storage disease that causes severe neurological decline in children stocktwits.com. The FDA’s BTD endorsement signals that early data for TA-ERT show “substantial improvement” over existing options for this deadly disease,